Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-Center, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Single-dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of a Single Dose of AD-6626 Administered Orally to Normal, Healthy Volunteers in Part A and the Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single Oral Dose of AD-6626 Followed by Alcohol Administration in Normal, Healthy Volunteers With the Aldehyde Dehydrogenase 2 (ALDH2)*1/*1 (Wild Type) or ALDH2*1/*2 (Heterozygous) Genetic Variant in Part B

Next Previous
Trial Profile

A Single-Center, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Single-dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of a Single Dose of AD-6626 Administered Orally to Normal, Healthy Volunteers in Part A and the Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single Oral Dose of AD-6626 Followed by Alcohol Administration in Normal, Healthy Volunteers With the Aldehyde Dehydrogenase 2 (ALDH2)*1/*1 (Wild Type) or ALDH2*1/*2 (Heterozygous) Genetic Variant in Part B

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AD 6626 (Primary)
  • Indications Fanconi's anaemia
  • Focus Adverse reactions
  • Sponsors ALDEA Pharmaceuticals

Most Recent Events

  • 08 Jun 2016 Status changed from recruiting to completed.
  • 02 Mar 2015 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top